Sentences with phrase «microsatellite instability»

Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.

The population - based study of 503 people with colon cancer found that 14 percent of Caucasians and 7 percent of African - Americans had a genetic marker called microsatellite instability, or MSI.

Both cancer types demonstrate a high frequency of microsatellite instability, where the repair mechanism for DNA is broken, and mutations in POLE, a gene responsible for producing a protein involved in DNA replication and repair.

The hypermutated microsatellite instability group exhibited a high mutation rate, as well as few copy number alterations, but did not carry mutations in the POLE gene.

In this updated multivariable analysis, the researchers included age, race, gender, synchronous vs metachronous disease, and consensus molecular subtypes, as well as other mutational events such as BRAF, NRAS, KRAS, HRAS, and microsatellite instability status.

For the remaining 14 samples, a match was nearly perfect, with only one or two of the microsatellite markers varying, typically by only one repeat unit, as might be expected through microsatellite instability within a pedigree.

But a caveat is that many patients have few if any T - cells in their tumors, which means the treatment is effective in only about 20 percent of patients who also have high microsatellite instability.

In all, there were 291 tumors with KRAS, 393 with NRAS, 393 with BRAF, 378 with microsatellite instability, and 533 with consensus molecular subtypes.

In 2017, the U.S. Food and Drug Administration (FDA) approved the cancer drug Keytruda (pembrolizumab) for a range of solid tumors that are either microsatellite instability - high (MSI - H) or mismatch repair deficient (dMMR).

Both development of CRC and microsatellite instability (MSI) are associated with chronic inflammation.

Application in detecting mutations and microsatellite instability (MSI) using circulating DNA from clinical cancer samples will be presented.

In fact, the Food and Drug Administration's approval of pembrolizumab in May 2017 for adult and pediatric patients with solid tumors and high microsatellite instability, was the first time it had approved a cancer treatment based on a genetic feature rather than the cancer's location of origin.

The primary tumor location was an independent prognostic marker in patients with RAS wild - type metastatic colorectal cancer after adjusting for age, gender, synchronous / metachronous disease, consensus molecular subtype, and microsatellite instability and molecular status, according to the results of an analysis (abstract 3503) of data from CALGB / SWOG 80405 presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.